Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced positive top-line results from the second of two pivotal Phase 3 trials evaluating the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE